| Clinically isolated syndrome
Ponvory vs Kesimpta
Side-by-side clinical, coverage, and cost comparison for clinically isolated syndrome.Deep comparison between: Ponvory vs Kesimpta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsKesimpta has a higher rate of injection site reactions vs Ponvory based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Kesimpta but not Ponvory, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ponvory
Kesimpta
At A Glance
Oral
Once daily
S1P receptor 1 modulator
SC injection
Once monthly
Anti-CD20 monoclonal antibody
Indications
- Clinically isolated syndrome
- Multiple Sclerosis, Relapsing-Remitting
- active secondary progressive multiple sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Multiple Sclerosis, Secondary Progressive
- Clinically isolated syndrome
Dosing
Clinically isolated syndrome, Multiple Sclerosis, Relapsing-Remitting, active secondary progressive multiple sclerosis Initiate with 14-day oral dose titration starting at 2 mg once daily per schedule; maintenance dose is 20 mg orally once daily beginning Day 15.
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Clinically isolated syndrome 20 mg SC injection at Weeks 0, 1, and 2 (loading doses), then 20 mg SC once monthly starting at Week 4.
Contraindications
- Myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III or IV heart failure within the last 6 months
- Mobitz type II second-degree or third-degree AV block, sick sinus syndrome, or sino-atrial block without a functioning pacemaker
- Active HBV infection
- History of hypersensitivity to ofatumumab or life-threatening injection-related reaction to KESIMPTA, including anaphylaxis and angioedema
Adverse Reactions
Most common (>=10%) Upper respiratory tract infection, hepatic transaminase elevation, hypertension
Serious Infections, bradyarrhythmia and AV conduction delays, respiratory effects, liver injury, increased blood pressure, cutaneous malignancies, macular edema, posterior reversible encephalopathy syndrome, severe increase in disability after stopping
Most common (>10%) upper respiratory tract infections, injection-related reactions (systemic), headache, injection-site reactions (local)
Serious infections, injection-related reactions and hypersensitivity reactions, reduction in immunoglobulins, liver injury
Postmarketing hypersensitivity reactions, liver injury
Pharmacology
Ponesimod is a sphingosine 1-phosphate (S1P) receptor 1 modulator that binds with high affinity to S1P receptor 1 and blocks lymphocyte egress from lymph nodes, reducing peripheral blood lymphocyte counts; the therapeutic mechanism in multiple sclerosis may involve reduction of lymphocyte migration into the central nervous system.
Ofatumumab is a recombinant human IgG1 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes, resulting in antibody-dependent cellular cytolysis and complement-mediated lysis; the precise mechanism in multiple sclerosis is unknown but is presumed to involve B-lymphocyte depletion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ponvory
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (10/12)
Kesimpta
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Ponvory
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
Kesimpta
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Ponvory
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Kesimpta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
PonvoryView full Ponvory profile
KesimptaView full Kesimpta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.